A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

- Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of
chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the
following criteria:

- plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score
≥12 in affected skin at screening and baseline

- sPGA score of ≥3 at screening and baseline

- Candidate for biologic treatment for psoriasis.

Exclusion Criteria:

- Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
endocrine, hematological, neurological, or neuropsychiatric disorders or any other
serious and/or unstable illness that, in the opinion of the investigator, could
constitute a risk when taking investigational product or could interfere with the
interpretation of data.

- Breastfeeding or nursing (lactating) women.

- Have had serious, opportunistic, or chronic/recurring infection within 6 months prior
to screening.

- Have received live vaccine(s) (included attenuated live vaccines) within 1 month of
screening or intend to during the study.

- Have any other skin conditions (excluding psoriasis) that would affect interpretation
of the results.

- Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days
prior to baseline.

- Have received topical psoriasis treatment within 14 days prior to baseline.

- Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17
targeting biologics within 8 weeks prior to baseline.

- Have previous exposure to any biologic therapy targeting IL-23 (including
ustekinumab), either licensed or investigational (previous briakinumab use is
permitted).